Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
Post transplant lymphoproliferative disorders (PTLD) complicates the course of 0.3 to 3% of renal transplant patients receiving immunosuppression. Epstein-Barr virus (EBV) related non-Hodgkin's lymphomas of B-cell type is more common than those of T-cell origin. CD30 positive Anaplastic Large Cell Lymphoma (ALCL) is a Non-Hodgkin's lymphoma (B or T cell type) that accounts for a small percentage of PTLD's. ALCL of T-cell type are a spectrum of disease ranging from primary cutaneous to systemic nodal ALCL. The systemic nodal ALCL is further subdivided into anaplastic lymphoma kinase-1 (ALK-1) positive or negative. ALK-1 protein is a gene fusion product of translocation (2;5) and carries prognostic implications. We present an unusual manifestation of ALK-1 negative CD30 positive ALCL in a post renal transplant patient in FNA cytology with all supportive adjuvant studies and differential diagnoses and review the cytology literature on this topic.
Balachandran
Indra
I
Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA. indra.balachandran@acphs.edu
Walker
Joe W
JW
Broman
Jerry
J
D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D044963:Biopsy, Fine-Needle; D002277:Carcinoma / Q000175:diagnosis; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007150:Immunohistochemistry; D017730:Ki-1 Antigen / Q000032:analysis*; D016030:Kidney Transplantation / Q000009:adverse effects*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000737:chemistry / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D008297:Male; D008479:Mediastinal Neoplasms / Q000737:chemistry / Q000209:etiology / Q000276:immunology / Q000473:pathology*; D008545:Melanoma / Q000175:diagnosis; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000032:analysis*; D020794:Receptor Protein-Tyrosine Kinases; D012074:Remission Induction; D018239:Seminoma / Q000175:diagnosis / Q000556:secondary; D013736:Testicular Neoplasms / Q000175:diagnosis; D014750:Vincristine / Q000627:therapeutic use
D014408:Biomarkers, Tumor; D017730:Ki-1 Antigen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D011241:Prednisone